



UMass MMPC



19th Annual National MMPC Meeting
Cincinnati Zoo & Botanical Garden
October 29th, 2019



OVERVIEW

ADMINISTRATION

ANIMAL

PHENOTYPING CORES

FEES

RESOURCES

CONTACT US

The National Mouse Metabolic Phenotyping Center (MMPC) at UMass is a National Institutes of Health-sponsored resource (NIH Grant 5U2C-DK093000) that provides an array of sophisticated research tools to the global scientific community for the purpose of investigating mouse models of human diseases with particular focus on diabetes, obesity, and diabetic complications. The mission of the UMass MMPC is to advance medical and biological research by offering comprehensive, standardized, and high-quality experimental testing services to the academic and industry scientists. The UMass MMPC is composed of multidisciplinary group of investigators and leading scientists with state-of-the-art technologies at the UMass Medical School and consists of six complementary Phenotyping Cores. The collective goal of our research program is to find a cure for diabetes and improve human health.



Dr. Jason K. Kim, Director

Metabolism Core performs elegant, physiological, and non-invasive metabolic experiments to assess insulin sensitivity hyperinsulinemic-euglycemic clamp & GTT/ITT), glucose/lipid/protein metabolism using labeled metabolites, body composition using ¹H-MRS, energy balance (food/water intake, energy expenditure, physical activity) at varying temperature and light/dark cycle using TSE Metabolic Cage System with Environmental Chamber, and exercise capacity using treadmill in mice. The Core also conducts comprehensive drug trial studies for PK/PD, efficacy, and toxicity analysis with academic and pharmaceutical institutions.

Analytical Core utilizes Luminex, Cobas Clinical Chemistry Analyzer, and molecular experiments to perform a high-throughput, multiplexed analysis of serum/tissue/urine levels of hormones, cytokines, chemokines, electrolytes, and metabolites, liver/kidney/thyroid function panels, and metabolic/inflammatory signaling pathways. Samples can be directly sent to the Core or obtained from mice by the Core.

Islet Core conducts sophisticated *in vivo*, *ex vivo*, and *in vitro* analysis of insulin secretion, islet function/structure, and pancreatic function using hyperglycemic clamp, perfusion, and molecular experiments in mice. The Core also performs histological and morphological analysis with islet isolation.


Cardiovascular Core applies state-of-the-art high-frequency and high-resolution digital imaging platform with color Doppler mode (VisualSonics Vevo2100) to perform 2-D and M-mode echocardiography to non-invasively assess cardiac function and structure in mice. The Core also measures ECG/blood pressure and vascular/endothelial function, and conducts elegant micro-surgery procedures to generate mouse models of cardiovascular and peripheral vascular diseases.

Microbiome Core provides expert knowledge and metagenomics 16S rRNA NextGen sequencing tools for state-of-the-art analysis of gut microbiota to investigate their role in altered energy balance and metabolism in mice. The Core also offers Fecal Microbiota Transplant (FMT) and antibiotic treatment procedures to facilitate alterations in gut microbiota population.

The Humanized Mouse Cell Transplantation and Assessment Core offers unique “humanized” mice engrafted with functional human cells/tissues to conduct clinically relevant *in vivo* experiments of human cells, tissues, and immune system. The Core also provides expert and standardized techniques to assess *in vivo* function of transplanted human islets and stem cell-derived beta-cells in immunodeficient mice.

UMass MMPC in Year 8

Mouse Phenotyping Consolidation Fund 51126



Beginning Fund Balance **-\$19,069**


-\$91,230

	Q1'19	Q2'19	Q3'19	Q4'19	FY'19 YTD	Q1'20
Revenue	\$1,151	\$73,412	\$16,253	\$122,432	\$213,248	\$155,902
5U2C Grant	\$110,090	\$141,050	\$86,942	\$137,394	\$475,476	\$0
Total Revenue	\$111,241	\$214,462	\$103,195	\$259,826	\$688,724	\$155,902
Expenses	\$56,901	\$114,015	\$71,027	\$62,534	\$304,478	\$41,084
5U2C Grant	\$110,090	\$141,050	\$86,942	\$137,394	\$475,476	\$0
Total Expenses	\$166,991	\$255,065	\$157,969	\$199,929	\$779,954	\$41,084
Net Balance	-\$55,750	-\$40,603	-\$54,774	\$59,898	-\$91,230	\$114,818

Current Fund Balance

\$23,589

UMass MMPC



Drug Trial Study



GlaxoSmithKline



Metabolism Core

**Research Staff
Lauren Tauer, M.S.**




**Director, Charles River
Laboratories**

**Core Director
Randall Friedline, Ph.D.**




Metabolism Core

Mouse Phenotyping Metabolism Core Dept ID #W400940002 Fund 51126



FY20 CUSTOMER REVENUE

Molecular Medicine	0.9%
Gene Therapy	7.3%
Infectious Disease	5.8%
MCCB	1.4%
GlaxoSmithKline LLC	43.9%
G. Washington Univ.	14.0%
New York University	11.8%
Harvard	8.9%
Other External (3)	6.1%



Microbiome Core



Director: Beth A. McCormick, PhD

The Microbiome Core offers:

- Consultation service for the design and implementation of gut microbiome studies
- Sample preparation and quality control tests
- Metagenomic 16S rRNA NextGen sequencing methodologies
- Post-sequencing consultation for data analysis, interpretation, upload, and presentation
- Fecal Microbiota Transplant (FMT) procedure to selectively alter gut microbiota in mice
- Chronic and acute antibiotic treatment to induce altered gut microbiota in mice

MMMRP Brings Together Wellesley College with Metabolism Core & Microbiome Core of UMass MMPC




Marc J. Tetel, Ph.D.
Professor & Chair
of Neuroscience

Kalpana Acharya, Ph.D.
Research Scientist



MMMRP Service Using Metabolism & Microbiome Core




- **Ovx:** Ovariectomy and implant capsules
- **5FS:** 5-hr fasting glucose
- **Clamp:** Hyperinsulinemic-euglycemic clamp
- **MRI :** Body composition (g; using ^1H -MRS)
- **FC:** Fecal samples

- ☐ Vehicle-treated Female Mice (n=6)
- ☐ E2-treated Female Mice (n=6)


Ovariectomy Procedure for Studies Using Female Mice





Ovariectomized Female Mice Become Obese on HFD, But Diet-Induced Obesity is Prevented with Estrogen Replacement





Estrogen Replacement Lowers Blood Glucose Levels in Ovariectomized Female Mice on Chow and HFD



Estrogen Replacement Increases Food Intake and Energy Expenditure in Ovariectomized Female Mice on HFD




Estrogen Replacement Increases Physical Activity and Insulin Sensitivity in Ovariectomized Female Mice






Alpha Diversity of Gut Microbiome is Affected by Different Diets But Not By Estrogen Treatment






Beta Diversity of Gut Microbiome is Significantly Affected by Estrogen Treatment in HFD-Fed Female Mice



Metabolic Effects of Fecal Microbiota Transplantation & Akkermansia in HFD-Fed Ovariectomized Female Mice



TREATMENT GROUPS (n=4 /group)

1. **VV** (Veh mice getting Veh-FMT)
2. **VA** (Veh mice getting E2-FMT with Akkermansia)
3. **EE** (E2 mice getting E2-FMT)


TIMELINE ABBREVIATIONS

- **OVX**: Ovariectomy & implant capsules (E2 or Veh)
- **5HFS**: 5-hr fasting blood glucose.
- **ABX**: AVNM cocktail in drinking water for 14 days
- **FMT**: Fecal microbiota transplant
- *****: Fecal samples collection days
- **MRI**: Body composition
- Every 4 days, body weight was also be measured.

Vehicle Mice Receiving FMT from E2-Treated Mice + Akkermansia Are Not Protected from Diet-Induced Obesity


Body Weights (g)

- Controls
- Vehicle with FMT from E2-treated mice + Akkermansia
- E2 with FMT from E2-treated mice




Vehicle Mice Receiving FMT from E2-Treated Mice + Akkermansia Are Not Protected from Diet-Induced Obesity

Fat Mass (g)




Activity is Increased in E2 Mice But Not in Vehicle Mice Receiving FMT from E2-Treated Mice + Akkermansia

Physical Activity



Increased Energy Expenditure in E2 Mice But Not in Vehicle Mice Receiving FMT from E2-Treated Mice + Akkermansia



Energy Expenditure



Vehicle Mice Receiving FMT from E2-Treated Mice + Akkermansia Remained Insulin Resistant After HFD


Glucose Tolerance Tests

- Controls
- Vehicle with FMT from E2-treated mice + Akkermansia
- E2 with FMT from E2-treated mice



Analytical Core

**Core Director
Xiaodi Hu, M.S.**




**Research Staff
Duy Tran, B.S.**




Analytical Core

Mouse Phenotyping Analytical Core Dept ID #W400940003 Fund 51126




FY20 CUSTOMER REVENUE

Diabetes	73.0%
Harvard University	14.1%
University of Tennessee	12.9%



Analytical Core

Sex Steroid Imbalances in obesity



Rubinow, KB. 2017. *Adv Exp Med Biol*. 1043:285.

How can the Analytical Core help?

Draw upon our extensive experience and knowledge to work with dependable suppliers to identify and review available ELISA assays

Process samples and return data in a timely manner

Provided ID	Matrix	Estradiol (pg/ml)	Progesterone (ng/ml)	Testosterone (ng/ml)
1	plasma	3.3	4.4	0.38
2	plasma	2.6	15.1	0.73
3	plasma	2.3	12.2	0.96
4	plasma	2.8	6.3	0.26
5	plasma	2.4	8.6	0.66
6	plasma	0.7	4.2	0.19
7	plasma	1.0	5.2	0.11
8	plasma	3.3	4.1	0.19
9	plasma	0.9	3.3	0.15
10	plasma	0.3	16.2	0.43
11	plasma	2.0	5.6	0.26
12	plasma	1.2	3.3	0.15
13	plasma	2.0	2.2	0.12
14	plasma	3.6	4.6	8.0
15	plasma	3.4	16.9	0.51
16	plasma	6.5	8.5	0.33
17	plasma	1.4	6.0	3.60
18	plasma	3.0	15.9	0.84
19	plasma	0.1	16.5	1.32
20	plasma	1.2	10.5	0.88

Analytical Core Working with Metabolism Core

Obesity – not just a lifestyle choice....





Tanzeel Ur Rehman/ Cover Asia Press

Prader-Willi Syndrome - most common known genetic cause of morbid obesity in children. Characterized by:


- infantile hypotonia
- hypogonadism and hypogenitalism
- growth hormone deficiencies
- **hyperphagia leading to early childhood obesity.**

UMass MMPC assisted a junior faculty at UConn in characterizing a new brain-specific Rnu11 KO mice using Analytical & Metabolism Core



Cardiovascular Core

Core Director
Tim Fitzgibbons, M.D., Ph.D.




In Utero Measurement of Fetal Heart Rate



- ☐ Congenital heart disease and maternal metabolic disorders are common causes of fetal morbidity
- ☐ Cholestasis of pregnancy - Maternal cholestasis causes an increase in plasma bile acids that is associated with decreased fetal HR and poor outcomes.

Do Bile Acids Affect Fetal Heart Rate?


Embryonic Day E18.5 in Pregnant C57BL/6J Mice



IV vehicle injection



IV bile acid injection




Baseline ultrasound

30 min post injection

- ✓ Fetal HR using ultrasound & simultaneous maternal HR using ECG


Controls (Vehicle-Treated Mice)

Baseline



Maternal HR 707 bpm
Fetal HR 233 bpm


30-min Post-injection



Maternal HR 694 bpm
Fetal HR 233 bpm

Bile Acids-Treated Mice

Baseline




Maternal HR 707 bpm
Fetal HR 232 bpm

30-min Post-injection



Maternal HR 627 bpm
Fetal HR 153 bpm

Bile Acids Reduce Fetal Heart Rate But Not Maternal Heart Rate



UMass MMPC from 2011 ~ 2019

UMass MMPC Functions	Project Year 1	Project Year 2	Project Year 3	Project Year 4	Project Year 6	Project Year 7	Project Year 8
Users of Metabolism Core (# local / # outside)	7 (4 / 3)	11 (3 / 8)	16 (6 / 10)	29 (9 / 20)	47 (10 / 37)	33 (8 / 25)	36 (15 / 21)
Services of Metabolism Core (# local / # outside)	72 (60 / 12)	57 (13 / 44)	63 (23 / 40)	139 (39 / 100)	233 (40 / 192)	317 (33 / 284)	312 (102 / 210)
Users of Analytical & Functional Core (# local / # outside)	5 (5 / 0)	10 (5 / 5)	12 (5 / 7)	20 (4 / 16)	30 (18 / 12)	34 (7 / 27)	27 (11 / 16)
Services of Analytical & Functional Core (# local / # outside)	16 (16 / 0)	27 (15 / 12)	27 (12 / 15)	152 (46 / 106)	205 (125 / 80)	189 (36 / 153)	147 (83 / 64)
Publications citing MMPC: With center co-authorship	5	11	8	6	13	12	14
Total Publications citing MMPC: No center co-authorship	0	0	0	2	2	3	5
Program Income	\$160,221	\$148,476	\$168,136	\$656,313	\$807,025	\$438,812	\$415,188

Providing Support for NIH Grant Applications

Investigator

Ann Marie Schmidt, MD
Basak Icli, PhD
David Hui, PhD
John Kopchick, PhD
John Ussher, PhD
Ming Xu, PhD
Noemi Polgar, PhD
Ricardo Gazinelli, PhD
Richard Lee, MD
Ta Yuan Chang, PhD
Ahmed Lawan, PhD
Andrea Zsombok, PhD
Andrew Wolfe, PhD
Beiyan Zhou, PhD
Emily Sims, MD
Fawaz Haj, PhD
Henry Ruiz, PhD
Jianguo Wu, PhD
Michael Stitzel, PhD
Vishwajeet Puri, PhD

Institution

New York University
Harvard Medical School
University of Cincinnati
Ohio University
University of Alberta
University of Connecticut
University of Hawaii
UMass Medical School
Harvard Medical School
Dartmouth College
Yale University
Tulane University
Johns Hopkins University
University of Connecticut
Indiana University
UC Davis
New York University
University of Connecticut
JAX-Connecticut
Ohio University

Department

Endocrinology & Diabetes
Cardiovascular Biology
Pathology
Biomedical Sciences
Pharmacology
Genetics
Biochemistry & Physiology
Infectious Disease
Cardiovascular Medicine
Biochemistry & Cell Biology
Pharmacology
Physiology & Medicine
Pediatrics & Physiology
Immunology
Pediatric Endocrinology
Nutrition
Endocrinology
Physiology & Neurobiology
Genomic Medicine
Biomedical Sciences

UMass MMPC Training

<u>Investigator</u>	<u>Institution</u>	<u>Core</u>
Weikang Cai	Harvard Medical School	Metabolism
Francois Moreau	Harvard Medical School	Metabolism
William King	LSU-Pennington Biomedical Center	Metabolism
Kathryn Pergola	LSU-Pennington Biomedical Center	Metabolism
Il-Young Kim	Gachon University, South Korea	Metabolism
Jiwoon Jang	Gachon University, South Korea	Metabolism
Sanghee Park	Gachon University, South Korea	Metabolism
Yeongnim Kim	Gachon University, South Korea	Metabolism
Stephen Vatner	Rutgers University	Metabolism
Ruexin Wang	Rutgers University	Metabolism
Kalpana Acharya	Wellesley College	Metabolism
Seung Ham	Navitor Pharmaceuticals, Cambridge	Metabolism
Tony Kang	Navitor Pharmaceuticals, Cambridge	Metabolism

UMass MMPC Training



Informed Consent Form for Training at the UMass MMPC

Health Risks and Animal Research

Working with laboratory animals carries some health risks, especially for individuals with a history of allergies. Working with nonhuman primates carries a risk of exposure to tuberculosis. It is recommended that all participants be up to date with their tetanus vaccination and those working with nonhuman primates have a test for TB within one year. We encourage everyone to seek the advice of a physician to determine if they are healthy enough to work with animals.

Dr. Jason K. Kim

Training Program Director

The Training Program Director has informed me of the potential risks of working with animals including but not limited to serious and potentially fatal allergic reactions, animal inflicted bite and scratch wounds, possible exposure to injectable anesthetics or anesthetic gases, and other conditions listed below by the program director:

I understand the risks and the recommendations for participating investigator. I also understand that no photography or video recording is allowed in the facility. I will comply to these policies as well as standard laboratory policies during my participation in the training program.

Affiliated Institution Pennington Biomedical Research Center

Principal Investigator John P. Kirwan, PhD

Signature [Signature] Date 9/25/2019

Participating Trainee Kathryn Pergola

Signature [Signature] Date 9/25/2019

This form must be completed by the Principal Investigator of the Affiliated Institution and the Participating Trainee as part of the IACUC protocol review for all trainees who do not work at the University of Massachusetts or its hospitals and signed by the trainee at least one week prior to the start of direct work with animals.

UMass MMPC Seminar Series



National MMPC Seminar Series



Franck Mauvais-Jarvis, MD, PhD

Director, Tulane Diabetes Research Program
Professor of Medicine, Section of Endocrinology
Price-Goldsmith Professor of Nutrition Research
Tulane University Health Sciences Center

*“Bi-directional Modulation of Insulin Secretion
by Testosterone in Males and Females”*

**Friday
November 9, 2018
12:00 pm**

Hosted by: Dr. Jason Kim

**Albert Sherman Center
9th Floor, AS9-2072
Conference Room**

National MMPC Seminar Series



Chang-Hwa Song, Ph.D.

Deputy Dean for Research Affairs
Professor of Microbiology and Department Head
of Medical Science, College of Medicine
Deputy Head, BK21-CNU Biomedical
Convergence Program
Chungnam National University, South Korea

*“Endoplasmic reticulum stress regulates
the innate immunity against
mycobacteria”*


**Tuesday
June 12, 2018
12:00 pm**

Hosted by: Dr. Jason Kim

**Albert Sherman Center
6th Floor, AS6-2072
Conference Room**



National Institute of
Diabetes and Digestive
and Kidney Diseases



Working to Cure Diabetes